SUNREST (SUNREST) fundamentals
SUNREST is a listed company, part of the Trading sector, listed on the NSE as SUNREST (ISIN INE0PLZ01012). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What SUNREST does
Sunrest Lifescience Limited is an India-based pharmaceutical company. The Company is engaged in the business of selling healthcare products, medicines, and cosmetics. It deals in capsules, tablets, syrup, ointment, gel, mouth wash, solution, suspension, dry powders, and toothpaste. The Company’s product portfolio comprises a range of drugs like Anti-Bacterial, Anti-Diarrheal, Antifungal, Anti Malerial, Anti-Diabetic, Dental Cure, Anti Protozol, Anti Histamine, Anti-Hypertensive drugs, Cosmetic, Anti-Parasitic, Multivitamin, Multimineral, Nutraceutical, and Anti-inflammatory. The Company operates in different states of India, such as Maharashtra, Gujarat, Madhya Pradesh, Odisha, and Rajasthan. The Company works on a third-party manufacturing basis or at times a purchase order basis with manufacturers of pharma products, depending upon the customer’s requirements.
Valuation and market data
| Last close | ₹37.20 |
|---|---|
| Market capitalisation | ₹16 crore |
| Enterprise value | ₹20 crore |
| P/E (TTM) | 3.06 |
| Price to book | 0.99 |
| Price to sales (TTM) | 0.17 |
| Book value per share | ₹37.72 |
| Dividend yield | 0.00% |
| Sector | Trading |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹73 crore | ₹10 crore | ₹8 crore | 0.00 |
| Mar 2025 | ₹33 crore | ₹3 crore | ₹2 crore | 0.00 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 53.5% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 46.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.